EGFR and lung adenocarcinoma: For example, in a 77-year-old female patient (case NCCLu-261) with stage IV lung adenocarcinoma displaying EGFR 19 deletion and acquired resistance to erlotinib after an initial response, the short-term PDC was insensitive to gefitinib but the long-term PDC was sensitive (standardized AUCs = 1.21 and −3.82, respectively; Figure 2C).